Potencial terapêutico de sistemas matriciais do ácido 5-aminossalicílico no tratamento de doenças inflamatórias intestinais: revisão sistemática

• Ano de defesa: 2018
• Autor(a) principal: Simoni, Suelen Eloise
• Orientador(a): Vasconcelos , Helder Lopes
• Banca de defesa: Vasconcelos , Helder Lopes , Sanches , Andréia Cristina Conegero , Borba , Helena Hiemisch Lobo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Estadual do Oeste do Paraná; Cascavel
• Programa de Pós-Graduação: Programa de Pós-Graduação em Ciências Farmacêuticas
• Departamento: Centro de Ciências Médicas e Farmacêuticas
• País: Brasil
• Palavras-chave em Português: Ácido 5-aminosalicílico; Mesalazina; Sistemas Matriciais; Colite Ulcerativa; Revisão Sistemática
• Palavras-chave em Inglês: 5-ASA; Mesalazine; MMX®; Multi Matrix technology; Ulcerative Colitis
• Área do conhecimento CNPq: CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: http://tede.unioeste.br/handle/tede/3652

The development of new technologies for the treatment of inflammatory bowel diseases, such as 5-aminosalicylic acid (5-ASA) multi matrix, becomes increasingly important because they are alternatives in unsuccessful treatments or even influence adaptation to a simpler dosing regimen. However, there is no clear conclusion as to its superiority or efficacy in modified release coated tablets, which are applied in clinical treatment protocols, nor on their safety and tolerability. For this reason, the objective of this dissertation was to perform a systematic review, searching through predefined keywords in database (Pubmed, Science Direct, Embase, Scopus, Web of Science and Clinical Trials) and also by research manual, from March 2016 to December 2017, studies comparing matrix technology with delayed release coated tablets in order to gather evidence that showed the equivalence or superiority of efficacy of this formulation in the parameters of clinical and endoscopic remission in patients suffering from of ulcerative colitis. In all, three studies fit into the inclusion criteria and were added to this study, all of them being a multicenter, double-blind, randomized methodological design, with matrix tablet concentrations varying from 1.2 g to 4.8 g daily, while the dose range of the coated tablets ranged from 800 mg to 2.4 g divided in two to three administrations daily. In summary, the efficacy of the two dosage forms is extremely similar in endoscopic remission parameters, however, when clinical remission is considered, the results indicate that better indices are achieved in the use of matrix technology, regardless of the concentration used.